Evaluation of an adaptive, multimodal intervention to reduce postoperative infections following cesarean delivery in Ethiopia: study protocol of the CLEAN-CS cluster-randomized stepped wedge interventional trial.
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
19 Aug 2022
19 Aug 2022
Historique:
received:
23
11
2021
accepted:
29
06
2022
entrez:
19
8
2022
pubmed:
20
8
2022
medline:
24
8
2022
Statut:
epublish
Résumé
We previously developed and pilot tested Clean Cut, a program to prevent postoperative infections by improving compliance with the WHO Surgical Safety Checklist (SSC) and strengthening adherence to infection control practices. This protocol describes the CheckList Expansion for Antisepsis and iNfection Control in Cesarean Section (CLEAN-CS) trial evaluating our program's ability to reduce infections following CS and other obstetric and gynecological operations in Ethiopia. CLEAN-CS is a cluster-randomized stepped wedge interventional trial with five clusters (two hospitals per cluster). It aims to assess the impact of Clean Cut on six critical perioperative infection prevention standards including antiseptic practices, antibiotic administration, and routine SCC use. The trial involves baseline data collection followed by Clean Cut training and implementation in each cluster in randomized order. The intervention consists of (1) modifying and implementing the SSC to fit local practices, (2) process mapping each standard, (3) coupling data and processes with site-specific action plans for improvement, and (4) targeted training focused on process gaps. The primary outcome is 30-day CS infection rates; secondary outcomes include other patient-level complications and compliance with standards. Assuming baseline SSI incidence of 12%, an effect size of 25% absolute reduction, and the ability to recruit 80-90 patients per cluster per month, we require a sample of 8100 patients for significance. We will report our study according to CONSORT. A cluster-randomized stepped wedge design is well-suited for evaluating this type of surgical safety program. The targeted standards are not in doubt, yet compliance is frequently difficult. Solutions are available and may be recognized by individuals, but teams dedicated to improvement are often lacking. Clean Cut was successfully piloted but requires a more rigorous methodological assessment. We seek to understand the qualities, characteristics, and resources needed to implement the program, the magnitude of effect on processes and outcomes, and to what degree it can enhance compliance with care standards. Challenges include a fraught social and political environment, pandemic travel restrictions, and a limited budget. ClinicalTrials.gov NCT04812522 (registered on March 23, 2021); Pan-African Clinical Trials Registry PACTR202108717887402 (registered on August 24, 2021).
Sections du résumé
BACKGROUND
BACKGROUND
We previously developed and pilot tested Clean Cut, a program to prevent postoperative infections by improving compliance with the WHO Surgical Safety Checklist (SSC) and strengthening adherence to infection control practices. This protocol describes the CheckList Expansion for Antisepsis and iNfection Control in Cesarean Section (CLEAN-CS) trial evaluating our program's ability to reduce infections following CS and other obstetric and gynecological operations in Ethiopia.
METHODS/DESIGN
METHODS
CLEAN-CS is a cluster-randomized stepped wedge interventional trial with five clusters (two hospitals per cluster). It aims to assess the impact of Clean Cut on six critical perioperative infection prevention standards including antiseptic practices, antibiotic administration, and routine SCC use. The trial involves baseline data collection followed by Clean Cut training and implementation in each cluster in randomized order. The intervention consists of (1) modifying and implementing the SSC to fit local practices, (2) process mapping each standard, (3) coupling data and processes with site-specific action plans for improvement, and (4) targeted training focused on process gaps. The primary outcome is 30-day CS infection rates; secondary outcomes include other patient-level complications and compliance with standards. Assuming baseline SSI incidence of 12%, an effect size of 25% absolute reduction, and the ability to recruit 80-90 patients per cluster per month, we require a sample of 8100 patients for significance. We will report our study according to CONSORT.
DISCUSSION
CONCLUSIONS
A cluster-randomized stepped wedge design is well-suited for evaluating this type of surgical safety program. The targeted standards are not in doubt, yet compliance is frequently difficult. Solutions are available and may be recognized by individuals, but teams dedicated to improvement are often lacking. Clean Cut was successfully piloted but requires a more rigorous methodological assessment. We seek to understand the qualities, characteristics, and resources needed to implement the program, the magnitude of effect on processes and outcomes, and to what degree it can enhance compliance with care standards. Challenges include a fraught social and political environment, pandemic travel restrictions, and a limited budget.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04812522 (registered on March 23, 2021); Pan-African Clinical Trials Registry PACTR202108717887402 (registered on August 24, 2021).
Identifiants
pubmed: 35986400
doi: 10.1186/s13063-022-06500-9
pii: 10.1186/s13063-022-06500-9
pmc: PMC9389504
doi:
Banques de données
ClinicalTrials.gov
['NCT04812522']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
692Subventions
Organisme : UBS Optimus Foundation
ID : 50319
Informations de copyright
© 2022. The Author(s).
Références
Int J Qual Health Care. 2019 Apr 1;31(3):166-172
pubmed: 30020489
Jt Comm J Qual Patient Saf. 2021 Nov;47(11):748-752
pubmed: 34493446
J Matern Fetal Neonatal Med. 2019 Apr;32(7):1130-1135
pubmed: 29103331
PLoS One. 2019 May 1;14(5):e0215643
pubmed: 31042774
J Clin Epidemiol. 2016 Jan;69:137-46
pubmed: 26344808
Trials. 2016 May 04;17(1):234
pubmed: 27146064
JAMA. 2015 Dec 1;314(21):2263-70
pubmed: 26624825
J Am Coll Surg. 2018 Jun;226(6):1103-1116.e3
pubmed: 29574175
BMJ. 2016 May 18;353:i2686
pubmed: 27193459
Bull World Health Organ. 2016 Mar 1;94(3):201-209F
pubmed: 26966331
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
World J Surg. 2017 Dec;41(12):3038-3045
pubmed: 29030677
World J Surg. 2012 Nov;36(11):2545-53
pubmed: 22851147
Patient Saf Surg. 2019 Oct 28;13:34
pubmed: 31673291
Lancet Infect Dis. 2018 May;18(5):507-515
pubmed: 29519766
J Am Coll Surg. 2004 Apr;198(4):626-32
pubmed: 15051016
Br J Surg. 2021 Jun 22;108(6):727-734
pubmed: 34157086
BMJ. 2018 Nov 9;363:k1614
pubmed: 30413417